New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer

Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) announced results of the PACE-B trial published in the New England Journal of Medicine. The study shows that at five years, stereotactic body radiation therapy (SBRT) provides comparable rates of cancer control, tolerability, and sexual functioning to conventional radiotherapy (CRT) for men with localized prostate cancer. SBRT, delivered using Accuray's CyberKnife System, reduces treatment time from up to 39 days to just five days.

Key findings include:

• High cancer control rates: 95.8% for SBRT vs 94.6% for CRT
• Similar rates of erectile dysfunction: 26.4% for SBRT vs 29.1% for CRT
• Stable urinary and bowel symptoms at five years for both groups

The study provides strong evidence supporting SBRT as an effective, time-efficient treatment option for men with low- or intermediate-risk prostate cancer.

Positive

• SBRT using CyberKnife System shows comparable cancer control rates to conventional radiotherapy (95.8% vs 94.6%)
• SBRT reduces treatment time from up to 39 days to just 5 days
• Similar rates of erectile dysfunction and stable urinary/bowel symptoms at 5 years for SBRT and CRT
• Study published in prestigious New England Journal of Medicine, providing strong evidence for SBRT in prostate cancer treatment

Negative

• None.

Insights

Medical Research Analyst

The PACE-B trial results published in the New England Journal of Medicine represent a significant advancement in prostate cancer treatment. The study demonstrates that stereotactic body radiation therapy (SBRT) delivered in just 5 sessions achieves comparable outcomes to conventional radiotherapy (CRT) given over 20-39 sessions.

Key findings include:

• Similar 5-year cancer control rates: 95.8% for SBRT vs. 94.6% for CRT
• Comparable tolerability and sexual function preservation
• Treatment time reduced from up to 39 days to just 5 days

This data provides level 1 clinical evidence, the highest standard for guiding clinical practice changes. For Accuray, whose CyberKnife System was used in the SBRT arm, this validates their technology's efficacy in delivering precise, high-dose radiation.

The study's implications are far-reaching, potentially shifting the standard of care towards SBRT for localized prostate cancer. This could lead to increased adoption of Accuray's CyberKnife technology, potentially boosting the company's market share and revenues in the radiation therapy sector.

Financial Analyst

This study publication is a significant positive catalyst for Accuray (NASDAQ: ARAY). The validation of their CyberKnife System's effectiveness in a prestigious journal like NEJM could drive increased adoption of their technology. Key financial implications include:

• Market expansion: Potential for SBRT to become the new standard of care for localized prostate cancer, expanding Accuray's addressable market.
• Revenue growth: Increased adoption of CyberKnife systems could lead to higher equipment sales and service revenues.
• Competitive advantage: The study highlights CyberKnife's unique ability to track and correct for prostate motion, differentiating it from competitors.
• Healthcare cost reduction: Shorter treatment times (5 vs. 39 days) could appeal to healthcare providers looking to improve efficiency and reduce costs.

With a current market cap of $187,511,950, Accuray is well-positioned to capitalize on this clinical validation. Investors should monitor for potential increases in order backlog, revenue growth and market share gains in the coming quarters as a result of this study.

The Precision of Stereotactic Body Radiation Therapy (SBRT), an Advanced Treatment Technique, Enables Treatment in Five Days, Significantly Reducing the Time Men Must Spend Undergoing Care

MADISON, Wis., Oct. 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that results of the PACE-B – Prostate Advances in Comparative Evidence – trial were published in the New England Journal of Medicine (NEJM). The research builds on previously reported data and shows that at five years, stereotactic body radiation therapy (SBRT) provides comparable rates of cancer control, tolerability and sexual functioning to conventional radiotherapy (CRT), while reducing the overall treatment timeframe from up to 39 days of treatment to just five days. The Accuray CyberKnife^® System was used in the SBRT treated arm of the PACE-B study and showed excellent disease control with low rates of toxicity for men with prostate cancer.

Prostate cancer is the second most common cancer diagnosed in men, with almost 1.5 million new cases identified worldwide in 2022¹. While it is typically a slow-growing and manageable disease, it's important that men have access to treatment options, such as SBRT delivered using the CyberKnife System, that can not only manage the cancer but also enable them to get back to a healthy, full life, faster.

SBRT uses advanced techniques to deliver ultra-hypofractionated radiation therapy – very high doses of radiation are given over a few days – necessitating an extremely high degree of targeting accuracy and precision. The PACE-B trial enrolled men with low- or intermediate-risk prostate cancer who received SBRT in either five sessions or CRT in 20 or 39 sessions.

Chief Investigator Professor Nicholas van As, Medical Director and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust, and Professor in Precision Prostate Radiotherapy at The Institute of Cancer Research, London, said:

"At The Royal Marsden and the ICR, we are focused on developing smarter, better and kinder treatments for patients across the UK and internationally. Standard radiation treatment is already highly effective and is very well tolerated in people with localized prostate cancer but for a healthcare system and for patients, to have this treatment delivered just as effectively in five days as opposed to four weeks is hugely significant.

"To be able to sit with a patient and say, 'We can treat you with a low toxicity treatment in five days, and your chance of keeping the cancer at bay for five years is 96 percent,' is a very positive conversation to have. We expect our trial to be practice changing and people with intermediate risk prostate cancer should be given the option of SBRT as an alternative to conventional radiation or prostate surgery."

SBRT: Comparable Results to Conventional Radiotherapy in 75 Percent Less Time
Both groups attained high rates of cancer control at five years, with similar rates of 94.6 percent for CRT and 95.8 percent for SBRT achieved without the use of androgen deprivation therapy (ADT), also known as "hormone therapy." SBRT was well-tolerated and treatment-related impairment (such as urinary, bowel and sexual function) and bother were comparable to CRT. "Bother" refers to the annoyance that patients experience because of a decline in their ability to perform certain functions. At five years, 29.1 percent of men treated with CRT and 26.4 percent of men receiving SBRT reported erectile dysfunction, while participants in both groups stated they had stable urinary and bowel symptoms at this time point.

"As a radiation oncologist who has had the privilege of treating numerous men with prostate cancer, I am grateful that the medical community continues to invest resources into refining our approach to this common diagnosis. The results of the PACE-B trial are published in one of the premier medical journals and are a game-changer. They provide the most compelling level of data to date in support of prostate SBRT for early-stage disease, and directly inform the standard of care. This trial empowers men who require or prefer radiation treatment to utilize SBRT, a technique that not only offers highly effective cancer therapy, but also significantly reduces the disruption to their lives compared to traditional schedules. This trial represents a crucial step forward in improving medical care and enhancing the quality of life for men diagnosed with prostate cancer," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray.

Continued Dr. Blacksburg, "The CyberKnife^® System is supported by more than 30 years of global clinical data, including the results from the PACE-B trial. The system equips medical care teams to treat prostate cancer with tremendous confidence, assuring them of a tool that consistently delivers extremely accurate treatments. This reliability not only enhances the likelihood of successful outcomes but also minimizes potential side effects, providing an optimal approach to curing this common medical condition."

The prostate gland can move unpredictably and rapidly throughout the treatment, sometimes moving as much as 10 mm in as little as 30 seconds due to normal patient bodily functions^2,3,4,5. The ability to track, detect and correct for this motion is key to ensuring the radiation is delivered to the tumor.

Throughout the course of treatment, the CyberKnife System continually collects images to determine exactly where the tumor is, helping to ensure that clinicians deliver radiation exactly where they want it. The system detects the tumor motion and automatically adjusts the radiation beam in real time to match the motion of the tumor, giving clinicians confidence to apply smaller treatment margins and enabling higher doses and fewer treatments. The CyberKnife System is the only radiotherapy device that can track and automatically correct for prostate motion and maintain sub-millimeter accuracy throughout treatment delivery. 

About the PACE-B Trial
The PACE trial data provides level 1 clinical evidence – the strongest level of evidence on which to guide practice changes. PACE-B is a prospective, randomized trial conducted in 35 centers in the UK, Canada and Ireland, comparing five-fraction SBRT to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer. The PACE-B trial is funded by Accuray, sponsored by The Royal Marsden and coordinated by the Clinical Trials and Statistics Unit at The Institute of Cancer Research, London (ICR-CTSU). Of the 874 patients enrolled, data up to five years on 874 patients treated with radiotherapy were analyzed; 433 receiving SBRT and 441 standard radiotherapy. Forty-one percent of men treated with SBRT in the study received treatment using the CyberKnife platform.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Media Contact
Beth Kaplan                                                                       
Public Relations Director, Accuray                                       
+1 (408) 789-4426                                                                   
bkaplan@accuray.com

¹ World Cancer Research Fund International. https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/
² Drexler and Furweger. "Quality assurance of a robotic, image guided radiosurgery system." WC 2009, IFMBE Proceedings 25/I, 492-495, 2009. https://link.springer.com/chapter/10.1007/978-3-642-03474-9_138
³ Kilby W, Dooley JR, Kuduvalli G, Sayeh S, Maurer CR. The CyberKnife^® Robotic Radiosurgery System in 2010. Technology in Cancer Research & Treatment. 2010;9(5):433-452. doi:10.1177/153303461000900502. https://pubmed.ncbi.nlm.nih.gov/20815415/
⁴ Yu C, Main W, Taylor D, Kuduvalli G, Apuzzo ML, Adler JR Jr. An anthropomorphic phantom study of the accuracy of Cyberknife spinal radiosurgery. Neurosurgery. 2004 Nov;55(5):1138-49. doi: 10.1227/01.neu.0000141080.54647.11. PMID: 15509320. https://pubmed.ncbi.nlm.nih.gov/15509320/
⁵ Antypas C, Pantelis E. Performance evaluation of a CyberKnife G4 image-guided robotic stereotactic radiosurgery system. Phys Med Biol. 2008 Sep 7;53(17):4697-718. doi: 10.1088/0031-9155/53/17/016. Epub 2008 Aug 11. PMID: 18695294. https://pubmed.ncbi.nlm.nih.gov/18695294/

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-study-reaffirms-five-session-radiation-treatment-provides-comparable-rates-of-cancer-control-tolerability-and-sexual-functioning-to-conventional-radiotherapy-treatment-in-men-with-localized-prostat-302278841.html

SOURCE Accuray Incorporated

FAQ

What are the key findings of the PACE-B trial for ARAY's CyberKnife System in prostate cancer treatment?

The PACE-B trial showed that SBRT using ARAY's CyberKnife System provides comparable cancer control rates (95.8%) to conventional radiotherapy (94.6%) at 5 years, with similar tolerability and sexual functioning, while reducing treatment time from up to 39 days to just 5 days.

How does SBRT using ARAY's CyberKnife System affect treatment duration for prostate cancer patients?

SBRT using ARAY's CyberKnife System significantly reduces treatment duration from up to 39 days with conventional radiotherapy to just 5 days, offering a more time-efficient option for prostate cancer patients.

What are the erectile dysfunction rates for SBRT compared to conventional radiotherapy in the PACE-B trial for ARAY?

The PACE-B trial reported similar erectile dysfunction rates at 5 years: 26.4% for SBRT using ARAY's CyberKnife System compared to 29.1% for conventional radiotherapy.

How does the CyberKnife System by ARAY address prostate motion during treatment?

ARAY's CyberKnife System continuously tracks, detects, and automatically corrects for prostate motion in real-time during treatment, maintaining sub-millimeter accuracy and allowing for smaller treatment margins and higher doses.